Abstract：Objective To investigate the effect of Rabeprazole-based triple therapy in the treatment of peptic ulcer disease.Methods A total of 80 patients with peptic ulcer disease admitted to Tianjin Fourth Central Hospital from January 2017 to January 2019 were selected as research objects,and they were divided into the Omeprazole group(40 cases)and the Rabeprazole group(40 cases)according to the random number table method.The Omeprazole group was treated with Omeprazole triple therapy,the Rabeprazole group was treated with Rabeprazole triple therapy.The efficacy and safety of the two methods were analyzed.Results The total effective rate of the Rabeprazole group was higher than that of the Omeprazole group,with statistically significant difference(P＜0.05).While the clinical symptom score,the levels of serum interleukin-6,C-reactive protein,and tumor necrosis factor-α levels of the Rabeprazole group were lower than those of the Omeprazole group,with statistically significant difference(P＜0.05).There was no significant difference in the total incidence of adverse reactions after treatment between the two groups(P＞0.05).Conclusion Rabeprazole-based triple therapy in the treatment of peptic ulcer disease has better therapeutic effect,can improve clinical symptom,reduce serum interleukin-6,C-reactive protein,and tumor necrosis factor-α levels.It is worthy of clinical promotion.
京公网安备 11010502046607号